2025年ASCO中国之声：百利天恒全球首创双抗ADC实现肺癌治疗双重突破

Core Viewpoint - The ASCO annual meeting showcased the promising clinical results of the first-in-class EGFRXHER3 dual antibody ADC, iza-bren, developed by Bai Li Tian Heng, particularly in non-small cell lung cancer (NSCLC) and small cell lung cancer (SCLC) [1][2]. Group 1: Clinical Results in NSCLC - Iza-bren demonstrated an objective response rate (ORR) of 63.2% in patients with EGFR-mutant NSCLC during initial human studies [2]. - The latest ASCO meeting reported further results showing an ORR of 46.2% and a disease control rate (DCR) of 85.9% in patients with advanced or metastatic NSCLC harboring non-classical EGFR mutations [4]. - The median progression-free survival (mPFS) for this cohort was reported at 7 months, with 81.3% of patients experiencing tumor shrinkage [4]. Group 2: Clinical Results in SCLC - In SCLC, iza-bren was evaluated in patients who had previously undergone platinum-based chemotherapy, achieving an ORR of 55.2% and a DCR of 81% [6]. - The median overall survival (mOS) for SCLC patients was reported at 12 months, with a median duration of response (mDoR) of 4.6 months [6]. - The most common treatment-related adverse events (TRAEs) were hematological, with anemia occurring in 84.5% of patients [6]. Group 3: Expert Commentary - Professor Lillian L. Siu highlighted the impressive ORR of 69% and mPFS of 10.5 months for patients with EGFR exon 20 insertion mutations treated with iza-bren [7]. - Siu also noted that ADCs are becoming a significant strategy in cancer treatment, with the potential for dual antibody ADCs to enhance therapeutic efficacy [7].